ReviewTherapeutic advances in gastroenterology2025
Endobiliary radiofrequency ablation for malignant biliary obstruction.
Review in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous biliary drainage and radiofrequency ablation (RFA) have long been used for malignant biliary obstruction (MBO). Endoscopic radiofrequency ablation (eRFA) has been performed for this condition, and it has also been performed in combination with endoscopic biliary stenting, and/or chemotherapy. Although eRFA is apparently being used in a wide variety of applications, there are insufficient reports on its use, and mostly from retrospective studies. This article summarizes and seeks to clarify the status of RFA for MBO. eRFA for MBO with endoscopic biliary stenting was shown in a recent meta-analysis to improve overall survival (OS) at 6 months of follow-up, but there was no improvement of stent patency. A combination of eRFA and chemotherapy reportedly improved OS and progression-free survival, especially for patients with locally-advanced biliary tract cancer. When eRFA was performed for occluded self-expandable metal stents (SEMSs), the time to recurrent obstruction in the eRFA group was significantly longer than that in the patients treated by uncovered SEMS placement alone. eRFA has also been performed for inoperable ampullary tumors, and the median OS was significantly longer in an eRFA group than in a stenting alone group, and there was improvement of obstructive jaundice. eRFA reportedly has a high clinical success rate for patients after endoscopic papillectomy. Future studies should examine the synergistic effects of using immune-checkpoint inhibitors and eRFA together. eRFA has been shown to have therapeutic effects in various applications, but further large prospective research is needed to improve the level of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.